STRO analyst estimates
Sutro Biopharma (STRO) analyst ratings, the average price target and its range, and every firm's latest call.
- 6 firms rate STRO: 6 buy, 0 hold, 0 sell.
- The average price target is $51.33 from None analysts, from $48.00 to $56.00.
STRO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Aug 7, 2026 | Stifel Nicolaus | Sutro Biopharma initiated with a Buy at Stifel | $48.00 |
| Jun 11, 2026 | Truist Financial | Sutro Biopharma assumed with a Buy at Truist | $50.00 |
| May 28, 2026 | Barclays | Barclays Starts Sutro Biopharma (STRO) at Overweight | $56.00 |
| May 15, 2026 | Leerink Partners | Sutro Biopharma price target raised to $43 from $38 at Leerink | $43.00 |
| May 15, 2026 | H.C. Wainwright | Sutro Biopharma price target raised to $50 from $28 at H.C. Wainwright | $50.00 |
| May 15, 2026 | Wedbush | Sutro Biopharma upgraded to Outperform from Neutral at Wedbush | $60.00 |
| Apr 30, 2026 | Mizuho Securities | Sutro Biopharma initiated with an Outperform at Mizuho | $50.00 |
| Mar 14, 2025 | Piper Sandler | Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler | $2.00 |
| Oct 11, 2024 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO) | $12.00 |
| Oct 11, 2024 | Bank of America Securities | BofA Securities Reiterates Buy Rating on Sutro Biopharma (STRO) | $12.00 |
| Aug 16, 2024 | Truist Financial | Sutro Biopharma (STRO) PT Lowered to $15 at Truist Securities | $15.00 |
| May 14, 2024 | Wedbush | Wedbush Reiterates Outperform Rating on Sutro Biopharma (STRO) | $8.00 |
| May 14, 2024 | Deutsche Bank | Sutro Biopharma (STRO) PT Lowered to $10 at Deutsche Bank | $10.00 |
| Apr 3, 2024 | Piper Sandler | Sutro Biopharma (STRO) PT Lowered to $11 at Piper Sandler | $11.00 |
| Apr 3, 2024 | Oppenheimer | Oppenheimer Reiterates Outperform Rating on Sutro Biopharma (STRO) | $10.00 |